Table 5.
Multivariate analyses of risk factors for transplant-related mortality
| Variable | SD |
URD |
||||||
|---|---|---|---|---|---|---|---|---|
| n | RR | 95% CI | P | n | RR | 95% CI | P | |
| Treatment category | .005 | .0006 | ||||||
| 1: MA + TBI + PBSC | 709 | 1.00 | 534 | 1.00 | ||||
| 2: MA + TBI + BM | 245 | 0.84 | 0.62-1.12 | .23 | 733 | 1.16 | 0.97-1.39 | .11 |
| 3: MA + nonTBI + PBSC | 1017 | 1.16 | 0.96-1.40 | .13 | 350 | .94 | 0.75-1.18 | .61 |
| 4: MA + nonTBI + BM | 492 | 0.82 | 0.65-1.05 | .11 | 265 | 0.90 | 0.70-1.16 | .41 |
| 5: RIC + PBSC | 622 | 0.87 | 0.69-1.09 | .22 | 405 | 0.74 | 0.58-0.94 | .01 |
| 6: RIC + BM | 67 | 0.67 | 0.37-1.20 | .18 | 83 | 0.88 | 0.59-1.33 | .55 |
| GVHD prophylaxis | < .0001 | |||||||
| CSA + MTX ± other | 2645 | 1.00 | ||||||
| Tacrolimus ± MTX ± other | 484 | 0.60 | 0.49-0.75 | < .0001 | ||||
| Other | 23 | 1.43 | 0.71-2.88 | .32 | ||||
| Recipient age, y | < .0001 | .0005 | ||||||
| 20-39 | 1342 | 1.00 | 940 | 1.00 | ||||
| 40-49 | 866 | 1.42 | 1.19-1.70 | < .0001 | 644 | 1.27 | 1.08-1.50 | .004 |
| 50+ | 944 | 2.05 | 1.73-2.44 | < .0001 | 786 | 1.38 | 1.16-1.65 | .0003 |
| Donor age, y | ||||||||
| 18-29 | 710 | 1.00 | ||||||
| ≥ 30 | 1669 | 1.33 | 1.14-1.54 | .0003 | ||||
| KPS | < .0001 | .0006 | ||||||
| < 80 | 256 | 1.00 | 216 | 1.00 | ||||
| 80-100 | 2789 | 0.61 | 0.47-0.77 | < .0001 | 1906 | 0.72 | 0.58-0.91 | .005 |
| Unknown | 107 | 0.82 | 0.54-1.24 | .35 | 248 | 0.54 | 0.39-0.74 | .0001 |
| Disease | < .0001 | |||||||
| ALL | 505 | 1.00- | ||||||
| AML | 1362 | 0.61 | 0.49-0.75 | < .0001 | ||||
| CML | 828 | 0.67 | 0.53-0.84 | .0006 | ||||
| MDS | 457 | 0.62 | 0.46-0.82 | .001 | ||||
| Disease status at transplant | < .0001 | < .0001 | ||||||
| Early | 1750 | 1.00 | 907 | 1.00 | ||||
| Intermediate | 520 | 1.30 | 1.07-1.57 | .007 | 568 | 1.12 | 0.94-1.34 | .21 |
| Advanced | 666 | 1.67 | 1.38-2.02 | < .0001 | 707 | 1.63 | 1.38-1.92 | < .0001 |
| Unknown | 216 | 1.50 | 1.10-2.07 | .01 | 188 | 1.71 | 1.33-2.20 | < .0001 |
| Sex mismatch (D/R) | .0003 | .02 | ||||||
| M/M, M/F, F/F | 2397 | 1.00 | 1947 | 1.00 | ||||
| F/M | 746 | 1.35 | 1.16-1.57 | <0.0001 | 423 | 1.21 | 1.03-1.42 | .02 |
| Missing | 9 | 0.55 | 0.08-3.93 | .55 | ||||
| R/D CMV serostatus | < .0001 | |||||||
| NN | 738 | 1.00 | ||||||
| NP/PN/PP | 1586 | 1.36 | 1.17-1.59 | < .0001 | ||||
| Missing | 46 | 2.26 | 1.35-3.77 | .002 | ||||
| ABO match | .01 | |||||||
| Match | 988 | 1.00 | ||||||
| Mismatch | 1370 | 1.18 | 1.03-1.35 | .02 | ||||
| Missing | 12 | 0.37 | 0.11-1.27 | .11 | ||||
| HLA match | < .0001 | |||||||
| 8/8 matched | 1532 | 1.00 | ||||||
| 7/8 matched | 614 | 1.44 | 1.24-1.68 | < .0001 | ||||
| ≤ 6/8 matched | 224 | 2.07 | 1.69-2.53 | < .0001 | ||||
Pairwise comparisons significant for the treatment categories were as follows for SD, treatment category 2 versus treatment category 3 (P = .03), treatment category 3 versus treatment category 4 (P = .002), treatment category 3 versus treatment category 5 (P = .006); and for URD, treatment category 2 versus treatment category 4 (P = .04), treatment category 2 versus treatment category 5 (P = .0001).
RR indicates relative risk; KPS, Karnofsky performance score; MDS, myelodysplastic syndrome; D, donor; R, recipient; M, male; F, female; N, negative; P, positive; CSA, cyclosporine; MTX, methotrexate; and MA, myeloablative.